Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic Chemotherapy vs TACE in Advanced HCC
NCT02585479Phase 3Withdrawn
- Sponsor
- Guangxi Medical University
- Start
- Oct 2015
- Primary completion
- Oct 2017
- Modality
- DNA Intercalators/Alkylators
01
Overview
A Phase 3 trial of pirarubicin, oxaliplatin in hepatocellular carcinoma (HCC), sponsored by Guangxi Medical University. Planned start Oct 2015; status: withdrawn.
02
Drugs
pirarubicinoxaliplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02585479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02585479.